Dosage Regimen Of An S1P Receptor Agonist

Patent No. EP1819326 (titled "Dosage Regimen Of An S1P Receptor Agonist") was filed by Novartis on Nov 28, 2005. The application was issued on Jul 2, 2014.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UK TRADING MYLANApr 1, 2015GALLAFENT
SANOVEL IIAC SAN VE TICMar 31, 2015BECKMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP1819326

NOVARTIS
Application Number
EP05826219A
Filing Date
Nov 28, 2005
Status
Revoked
Publication Date
Jul 2, 2014